SE460946B - En multipel-unit-dos komposition av kinidinglukonat - Google Patents

En multipel-unit-dos komposition av kinidinglukonat

Info

Publication number: SE460946B
Authority: SE; Sweden
Prior art keywords: release; hrs; exposure; less; composition
Prior art date: 1987-03-16

Application number

SE8701077A

Other languages

English (en)

Swedish (sv)

Other versions

SE8701077D0 (sv

SE8701077L (sv

Inventor

C H Appelgren

E C Eskilsson

S I Johansson

Original Assignee

Lejus Medical Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-03-16

Filing date

1987-03-16

Publication date

1989-12-11

1987-03-16 Application filed by Lejus Medical Ab filed Critical Lejus Medical Ab

1987-03-16 Priority to SE8701077A priority Critical patent/SE460946B/sv

1987-03-16 Publication of SE8701077D0 publication Critical patent/SE8701077D0/xx

1988-03-10 Priority to EP88850087A priority patent/EP0287536A1/fr

1988-03-15 Priority to DK139388A priority patent/DK139388A/da

1988-03-15 Priority to FI881238A priority patent/FI881238A7/fi

1988-03-16 Priority to NO881152A priority patent/NO881152L/no

1988-09-17 Publication of SE8701077L publication Critical patent/SE8701077L/

1989-12-11 Publication of SE460946B publication Critical patent/SE460946B/sv

Links

239000000203 mixture Substances 0.000 title claims description 15
XHKUDCCTVQUHJQ-LCYSNFERSA-N quinidine D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 XHKUDCCTVQUHJQ-LCYSNFERSA-N 0.000 claims description 12
229960002454 quinidine gluconate Drugs 0.000 claims description 12
239000001856 Ethyl cellulose Substances 0.000 claims description 7
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 7
229920001249 ethyl cellulose Polymers 0.000 claims description 7
235000019325 ethyl cellulose Nutrition 0.000 claims description 7
210000004051 gastric juice Anatomy 0.000 claims description 7
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 7
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 7
239000008363 phosphate buffer Substances 0.000 claims description 7
235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
230000002496 gastric effect Effects 0.000 claims description 2
239000013543 active substance Substances 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
239000008187 granular material Substances 0.000 description 5
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
229940050410 gluconate Drugs 0.000 description 4
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
ZHNFLHYOFXQIOW-AHSOWCEXSA-N (s)-[(2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid;dihydrate Chemical class O.O.OS(O)(=O)=O.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-AHSOWCEXSA-N 0.000 description 2
GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000008351 acetate buffer Substances 0.000 description 2
229940040526 anhydrous sodium acetate Drugs 0.000 description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
229960001404 quinidine Drugs 0.000 description 2
229960004482 quinidine sulfate Drugs 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920003136 Eudragit® L polymer Polymers 0.000 description 1
229920003151 Eudragit® RL polymer Polymers 0.000 description 1
229920003152 Eudragit® RS polymer Polymers 0.000 description 1
229920003137 Eudragit® S polymer Polymers 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000006096 absorbing agent Substances 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000010903 husk Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
229920002959 polymer blend Polymers 0.000 description 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SE8701077A 1987-03-16 1987-03-16 En multipel-unit-dos komposition av kinidinglukonat SE460946B (sv)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
SE8701077A SE460946B (sv)	1987-03-16	1987-03-16	En multipel-unit-dos komposition av kinidinglukonat
EP88850087A EP0287536A1 (fr)	1987-03-16	1988-03-10	Composition pharmaceutique de quinidine
DK139388A DK139388A (da)	1987-03-16	1988-03-15	Farmaceutisk praeparat
FI881238A FI881238A7 (fi)	1987-03-16	1988-03-15	Farmaceutisk beredning.
NO881152A NO881152L (no)	1987-03-16	1988-03-16	Farmasoeytisk blanding.

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8701077A SE460946B (sv)	1987-03-16	1987-03-16	En multipel-unit-dos komposition av kinidinglukonat

Publications (3)

Publication Number	Publication Date
SE8701077D0 SE8701077D0 (sv)	1987-03-16
SE8701077L SE8701077L (sv)	1988-09-17
SE460946B true SE460946B (sv)	1989-12-11

Family

ID=20367877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8701077A SE460946B (sv)	1987-03-16	1987-03-16	En multipel-unit-dos komposition av kinidinglukonat

Country Status (5)

Country	Link
EP (1)	EP0287536A1 (fr)
DK (1)	DK139388A (fr)
FI (1)	FI881238A7 (fr)
NO (1)	NO881152L (fr)
SE (1)	SE460946B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5196203A (en) *	1989-01-06	1993-03-23	F. H. Faulding & Co. Limited	Theophylline dosage form
US5202128A (en) *	1989-01-06	1993-04-13	F. H. Faulding & Co. Limited	Sustained release pharmaceutical composition
ATE124864T1 (de) *	1989-03-10	1995-07-15	Yamanouchi Pharma Co Ltd	Die wirkstoffabgabe steuerndes überzugsmaterial für lang wirksame formulierungen.
US4983401A (en) *	1989-05-22	1991-01-08	Kinaform Technology, Inc.	Sustained release pharmaceutical preparations having pH controlled membrane coatings
EP0653935B1 (fr) *	1992-08-05	2002-05-08	F.H. FAULDING & CO. LIMITED	Composition pharmaceutique sous forme de granules
US7122207B2 (en)	1998-05-22	2006-10-17	Bristol-Myers Squibb Company	High drug load acid labile pharmaceutical composition
UA69413C2 (uk) *	1998-05-22	2004-09-15	Брістол-Майерс Сквібб Компані	Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
DE10211289A1 (de)	2002-03-14	2003-09-25	Basf Ag	Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2336218C3 (de) *	1973-07-17	1985-11-14	Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz	Orale Arzneiform
SE8003805L (sv) *	1980-05-21	1981-11-22	Haessle Ab	En farmaceutisk beredning med forbettrade utlosningsegenskap
WO1984000295A1 (fr) *	1982-07-09	1984-02-02	Key Pharma	Forme de dosage de quinidine a liberation entretenue
SE457505B (sv) *	1984-01-10	1989-01-09	Lejus Medical Ab	Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
AU571312B2 (en) *	1984-02-10	1988-04-14	Nycomed Danmark A/S	Diffusion coated multiple-units dosage form

1987
- 1987-03-16 SE SE8701077A patent/SE460946B/sv not_active Application Discontinuation
1988
- 1988-03-10 EP EP88850087A patent/EP0287536A1/fr not_active Withdrawn
- 1988-03-15 FI FI881238A patent/FI881238A7/fi not_active Application Discontinuation
- 1988-03-15 DK DK139388A patent/DK139388A/da not_active Application Discontinuation
- 1988-03-16 NO NO881152A patent/NO881152L/no unknown

Also Published As

Publication number	Publication date
DK139388D0 (da)	1988-03-15
FI881238A0 (fi)	1988-03-15
FI881238A7 (fi)	1988-09-17
DK139388A (da)	1988-12-08
NO881152D0 (no)	1988-03-16
EP0287536A1 (fr)	1988-10-19
SE8701077D0 (sv)	1987-03-16
NO881152L (no)	1988-09-19
SE8701077L (sv)	1988-09-17

Legal Events

Date

Code

Title

Description

1995-02-28

NAV

Patent application has lapsed

Ref document number: 8701077-3

Effective date: 19901001

Publication	Publication Date	Title
KR100316206B1 (ko)	2002-11-09	모르핀의염을함유하는방출조절식제제
US6576260B2 (en)	2003-06-10	Sustained-release form of administration containing tramadol saccharinate
US5084278A (en)	1992-01-28	Taste-masked pharmaceutical compositions
US5670172A (en)	1997-09-23	Pharmaceutical spheroid formulation
US4794001A (en)	1988-12-27	Formulations providing three distinct releases
EP2265261B1 (fr)	2016-07-06	Systèmes d'administration de médicaments comprenant des médicaments faiblement basiques et des acides organiques
CN1886119B (zh)	2015-04-29	泮托拉唑多颗粒制剂
US20040022849A1 (en)	2004-02-05	Oral pharmaceutical composition with controlled release and prolonged absorption
BR112021013766A2 (pt)	2021-09-21	Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
EP2387994A1 (fr)	2011-11-23	Systèmes d'administration de médicaments comportant des médicaments faiblement basiques et acides organiques
BG65398B1 (bg)	2008-06-30	Ентерично покрит фармацевтичен състав и метод за получаване
LV12399B (en)	2000-06-20	IMPROVED SINGLE-DAY PUSH-BUTTON MINOCICLINE CARE SYSTEMS
CS268819B2 (en)	1990-04-11	Method of particles production with effective substance's controlled loosening
EP1423092A2 (fr)	2004-06-02	Poudres fonctionnelles administrees par voie orale
WO2003051343A1 (fr)	2003-06-26	Formes dosifiees d'antagoniste d'histamine h2 a liberation pulsatile
US20130004563A1 (en)	2013-01-03	Multiparticulate s-adenosylmethionine compositions and related methods
EP1154762B1 (fr)	2003-11-05	Compositions de capsules pharmaceutiques contenant de la loratadine et de la pseudoephedrine
JP5013871B2 (ja)	2012-08-29	経口徐放性医薬組成物
SK278868B6 (sk)	1998-04-08	Prípravok s retardovaným uvoľňovaním účinnej látky
SE460946B (sv)	1989-12-11	En multipel-unit-dos komposition av kinidinglukonat
SE447871B (sv)	1986-12-22	Farmaceutisk komposition med lang utsondringstid innefattande pinacidil i minst tva olika typer av pelletar
US4968506A (en)	1990-11-06	Pharmaceutical dosage with core of N-acetyl cystein
EP0413533A1 (fr)	1991-02-20	Microencapsulation, avec dissimulation de goût, de NSAID insoluble dans l'eau
ES2860694T3 (es)	2021-10-05	Composición farmacéutica de liberación sostenida que contiene rivastigmina
WO2004096175A2 (fr)	2004-11-11	Compositions au gout masque et leurs procedes de preparation